香菇菌多糖片联合常规抗结核疗法治疗女性盆腔结核

Lentinan combined with conventional antituberculous therapy for pelvic tuberculosis in women

目的评价香菇菌多糖片联合常规抗结核方案（2HRZE／4HRE）治疗盆腔结核的临床疗效。方法将符合入选标准的女性盆腔结核患者90例采用信封法进行随机方案隐藏，按1：1比例分为2组各45例。对照组采用2HRZE／4HRE抗结核方案，治疗组在对照组基础上加服香菇菌多糖片治疗，均治疗6个月。观察2组患者治疗前后血清糖类抗原125（carbohydrate antigen 125，CA125）、ESR变化，判定临床疗效。结果疗程结束后，治疗组CA125水平[（28．61±9．08）U／ml比（39．72±12．13）U／ml，t=4．919]、ESR[（36．13±8．33）mm／h比（41.35±12．45）mm／h，t=2．338]均低于对照组（P值均〈0．05）。治疗组（93．3％比20．0％：χ^2=46．335，P〈0．01）和对照组（82．2％比8．9％；χ^2=37．396，P〈0．01）治疗后血清CA125阴性率均显著高于同组治疗前，但治疗后组间阴性率比较差异无统计学意义（χ^2=1．6571，P=0．198）。治疗组总有效率显著高于对照组（93．3％比77．8％；χ^2=4．406，P=0．036）。结论香菇菌多糖片联合2HRZE／4HRE抗结核方案可有效治疗女性盆腔结核。

Objective To evaluate the therapeutic effect of lentinan combined with conventional antituberculous therapy in women with pelvic tuberculosis. Methods A total of 90 women with pelvic tuberculosis were enrolled and recruited into a control group and a treatment group by random number table, 45 in each group. The control group was treated with anti-tuberculosis program （2HRZE/4HRE）, while the treatment group was treated with lentinan tablets on the basis of the control group. Both groups were treated for 6 months. Serum levels of carbohydrate antigen 125 （CA125） and erythrocyte sedimentation rates （ESRs） were determined before and after treatment, and the therapeutic effect was evaluated. Results After treatment, the serum CA125 level （28.61 ± 9.08 U/nil vs. 39.72 ± 12.13 U/ml; t=4.919, P〈0.01） and the ESR （36.13 ± 8.33 mm/h vs. 41.35 ±12.45 mm/h; t=2.338, P〈0.05） in the treatment group were significantly lower than those in the control group. The negative rate of serum CA125 after treatment than before treatment in the treatment group （93.3% vs.20.0%; ）（2=46.335, P〈0.01） and the control group （82.2% vs.8.9%; χ^2=37.396, P〈0.01）; but there was no difference in negative rate of serum CA125 after treatment between two groups （χ^2=1.6571, P=0.198）. The total effective rate in the treatment group was significantly higher than that in the control group （93.3% vs. 77.8%; χ^2=4.406, P=-0.036）. Conclusion Lentinan combined with conventional antituberculous therapy is effective in treatment of pelvic tuberculosis in women.